ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Survival Benefit of Primary Tumor Resection Combined With Chemotherapy in Patients With Unresectable Colorectal Mucinous Adenocarcinoma With Liver Metastasis

Liao, Shu-wen; Zhan, Jie-qun; Liu, Chu-tian; Yu, Hai-tao; Wen, Min-jie*1
American journal of clinical oncology : the official publication of the American Radium Society2024-1DOI: 10.1097/COC.0000000000001055
12阅读
引用收藏
分享

摘要

Objective: To evaluate the survival benefit of combining primary tumor resection (PTR) and chemotherapy in patients with unresectable colorectal mucinous adenocarcinoma with liver metastasis (UCR-MAC-LM).Methods: We obtained data from the surveillance, epidemiology, and end results database for patients with UCR-MAC-LM from 2010 to 2017. Clinicopathological characteristics were analyzed using the chi(2) test. Propensity score matching was performed to balance baseline characteristics. Kaplan-Meier analysis and log-rank tests were used to estimate and compare survival outcomes. Univariate and multivariate Cox regression analyses were conducted to identify the prognostic factors.Results: A total of 10,178 patients with unresectable colorectal adenocarcinoma with liver metastasis were included, of whom 6.01% (n=612) had UCR-MAC-LM. The UCR-MAC-LM group had a higher proportion of female patients, a greater number of elderly patients, an increased incidence of right colon localization, larger tumor size, and higher T and N staging than the unresectable colorectal non-mucinous adenocarcinoma with liver metastasis group (P<0.05). Multivariate analysis identified several independent prognostic factors (P<0.05). Patients with unresectable colorectal adenocarcinoma with liver metastasis who underwent PTR+C had superior survival rates compared with those who received PTR/C alone or no treatment (cancer-specific survival, P<0.05; overall survival, P<0.05). Subgroup analysis revealed that 17 of 22 groups of patients with UCR-MAC-LM who received PTR+C had significantly prolonged long-term survival compared with those who received PTR/C alone.Conclusions: This surveillance, epidemiology, and end results-based study indicates that PTR+C may offer a survival advantage for a specific subgroup of patients with UCR-MAC-LM compared with PTR/C alone. Nonetheless, additional clinical trials are necessary to validate these findings.

学科与关键词

关键词
colorectal adenocarcinomamucinous adenocarcinomaliver metastasischemotherapyprimary tumor resection
相关
加载中…
  • Survival outcome of palliative primary tumor resection for colorectal cancer patients with synchronous liver and/or lung metastases: A retrospective cohort study in the SEER database by propensity score matching analysis
    Chen, Xianzhe; Hu, Weixian; Huang, Chengzhi; Liang, Weijun; Zhang, Jie; Wu, Deqing; Lv, Zejian; Li, Yong; Luo, Yuwen; Liang, Zongyu; Wang, Minjia; Wang, Junjiang; Yao, Xueqing*International Journal of Surgery, 2020, 80: 135-152.被引 10
  • The role of upfront primary tumor resection in asymptomatic patients with unresectable stage IV colorectal cancer: A systematic review and meta-analysis
    Liang, Zongyu; Liu, Zhiyuan; Huang, Chengzhi; Chen, Xin; Zhang, Zhaojun; Xiang, Meijuan; Hu, Weixian; Wang, Junjiang; Feng, Xingyu*; Yao, Xueqing*Frontiers in Surgery, 2023, 9: 1047373.被引 2
  • The tumor characteristics, treatment strategy, and prognosis in colorectal cancer patients with synchronous liver metastasis in China and the USA
    Jiao, Shuai; Guan, Xu*; Niu, Haitao; Ma, Xiaolong; Wang, Kaifeng; Liu, Enrui; Zhang, Weiyuan; Wei, Ran; Sun, Peng; Chen, Yinggang*; Wang, Xishan*INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2023, 38(1): 140.
查看全部 →

发表信息

论文状态
公开发表
期刊
American journal of clinical oncology : the official publication of the American Radium Society
发表日期
2024-01
卷期
第 47 卷, 第 1 期
页码
30-39
DOI
10.1097/COC.0000000000001055
语言
ENGLISH
成果收录
SCIE

作者

  • L

    Liao, Shu-wen (第一作者)

    1 · 2

  • Z

    Zhan, Jie-qun

    1

查看全部 5 位作者收起作者
  • L

    Liu, Chu-tian

    1 · 2

  • Y

    Yu, Hai-tao

    1 · 2

  • W

    Wen, Min-jie (通讯)

    1 · 2

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417